LYMPHOMA

SWOG S1826: A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma.

The purpose of this study is to compare nivolumab plus the three chemotherapy drugs doxorubicin, dacarbazine, and vinblastine sulfate (AVD) to brentuximab vedotin plus AVD, followed by targeted radiation therapy in some patients with lymphoma that does not completely respond to therapy.

Learn more about the SWOG S1826 trial or call the Reading Hospital Protocol Office at 484-628-8193.

MANTLE CELL LYMPHOMA
MYELOMA

BMS CA204008: Prospective Research Assessment in Multiple Myeloma: an OBservationaL Evaluation (PREAMBLE)

Learn more by contacting the Pottstown Hospital Clinical Research Office at 610-327-7544.

ECOG-ACRIN EAA173: Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM).

The purpose of this study is to determine whether patients with high-risk smoldering multiple myeloma when treated with daratumumab in addition to lenalidomide and dexamethasone live longer when compared to patients with high-risk smoldering multiple myeloma treated with lenalidomide and dexamethasone.

Learn more about the ECOG-ACRIN EAA173 trial or call the Reading Hospital Protocol Office at 484-628-8193.

EAA173: Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM)

Learn more about the Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma or contact the Pottstown Hospital Clinical Research Office at 610-327-7544.

ECOG-ACRIN EAA181: Effective Quadruplet Utilization After Treatment Evaluation (EQUATE): A Randomized Phase 3 Trial for Newly Diagnosed Multiple Myeloma Not Intended for Early Autologous Transplantation.

The purpose of this study is to determine if, after receiving 9 cycles of the usual treatment with three drugs (daratumumab, lenalidomide and dexamethasone), adding bortezomib to the three drugs for the second set of 9 treatment cycles (cycles 10-18) could be more effective in shrinking your cancer or preventing it from returning, compared to continuing on the same three-drug combination for another 9 treatment cycles.

Learn more about the ECOG-ACRIN EAA181 trial or call the Reading Hospital Protocol Office at 484-628-8193.

EMN29: A Phase 3 Randomized, Open-label Trial of Selinexor, Pomalidomide, and Dexamethasone (SPd) versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM).

The purpose of this study is to compare and evaluate the effectiveness and safety of the experimental treatment of selinexor in combination with pomalidomide and dexamethasone, compared to the effectiveness and safety of the standard treatment of elotuzumab in combination with pomalidomide and dexamethasone.
 

Learn more about the EMN29 trial or call the Reading Hospital Protocol Office at 484-628-8193.

JANSSEN-MMY3021: A Randomized Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Patients with Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant

The purpose of this study is to find out whether treatment with daratumumab and lenalidomide improves disease response in Multiple Myeloma.

Learn more about the JANSSEN- MMY3021 trial or contact the Reading Hospital Protocol Office at 484-628-8193.